The Effect of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells in a Collagenase-Induced Intracerebral Hemorrhage Rat Model.
- Author:
Kwanwoo KIM
1
;
Hyung Woo PARK
;
Hyo Eun MOON
;
Jin Wook KIM
;
Seongtae BAE
;
Jong Wook CHANG
;
Wonil OH
;
Yoon Sun YANG
;
Sun Ha PAEK
Author Information
- Publication Type:Original Article
- Keywords: intracerebral hemorrhage; hUCB-MSCs; neurogenesis; angiogenesis; apoptosis; inflammatory factor
- MeSH: Animals; Apoptosis; Blotting, Western; Brain; Cerebral Hemorrhage*; Cytokines; Extremities; Fluorescent Antibody Technique; Humans; Mesenchymal Stromal Cells*; Microglia; Models, Animal*; Nerve Growth Factors; Neurogenesis; Rats; Stroke; Umbilical Cord*
- From:Experimental Neurobiology 2015;24(2):146-155
- CountryRepublic of Korea
- Language:English
- Abstract: Intracerebral hemorrhage (ICH) is one of the devastating types of stroke. Human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) have potential benefits in recovery from brain damage following ICH. This study aimed to identify the beneficial effects of hUCB-MSCs and investigate whether they have anti-inflammatory effects on the ICH brain via neurotrophic factors or cytokines. hUCB-MSCs were transplanted into a collagenase-induced ICH rat model. At 2, 9, 16, and 30 days after ICH, rotarod and limb placement tests were performed to measure behavioral outcomes. ICH rats were sacrificed to evaluate the volume of lesion using H&E staining. Immunostaining was performed to investigate neurogenesis, angiogenesis, and anti-apoptosis at 4 weeks after transplantation. Inflammatory factors (TNF-alpha, COX-2, microglia, and neutrophils) were analyzed by immunofluorescence staining, RT-PCR, and Western blot at 3 days after transplantation. hUCB-MSCs were associated with neurological benefits and reduction in lesion volume. The hUCB-MSCs-treated group tended to reveal high levels of neurogenesis, angiogenesis, and anti-apoptosis (significant for angiogenesis). The expression levels of inflammatory factors tended to be reduced in the hUCB-MSCs-treated group compared with the controls. Our study suggests that hUCB-MSCs may improve neurological outcomes and modulate inflammation-associated immune cells and cytokines in ICH-induced inflammatory responses.
